Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 6 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Université Catholique de Louvain has 2 pending office actions within the Chemistry & Materials technology area. Both of these actions are being processed in 1 distinct art unit, which shows a high degree of technical concentration for the university's current filings. Interestingly, the university is interacting with only 1 distinct examiner for both of these matters.
The busiest examiner for the university is FAN, LYNN Y, who is managing 2 busiest examiner pending actions. This means that FAN, LYNN Y is responsible for the university's current pending workload. Having 2 pending office actions assigned to the same 1 distinct examiner within the same 1 distinct art unit provides a unique opportunity for the university to develop a consistent rapport and strategy with a single official. This streamlined prosecution profile reduces the need to adapt to different examiner styles or varying art unit procedures. The Chemistry & Materials technology area encompasses both of these 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (29%) |
| §102 only | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SNOW, BRUCE EDWARD | 1 | 75.4% | +8.0% |
| HAUK TEODORO, PRICILA NMN | 1 | 50.0% | +0.0% |
| BELLAH, JEFFREY LAWRENCE | 1 | 100.0% | +0.0% |
| BARIA, DINAH N | 1 | 72.9% | +28.5% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.6% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18580828 | PREVENTION AND/OR TREATMENT OF REWARD DYSREGULATION DISORDERS | HAUK TEODORO, PRICILA NMN | 14d |
| 18843768 | DEVICE FOR HEART VALVE REPAIR | SNOW, BRUCE EDWARD | — |
| 18562893 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | BELLAH, JEFFREY LAWRENCE | — |
| 18263756 | POLYPEPTIDE INHIBITORS OF LACTATE DEHYDROGENASE ACTIVITY FOR USE IN CANCER THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17792011 | GENETICALLY MODIFIED BACTERIUM WITH ALTERED ENVELOP INTEGRITY AND USES THEREOF | STEADMAN, DAVID J | 26d |
| 18477795 | ELASTIC ENERGY STORING FOR PROSTHESIS OR ORTHOSIS | BARIA, DINAH N | — |
| 18263756 | POLYPEPTIDE INHIBITORS OF LACTATE DEHYDROGENASE ACTIVITY FOR USE IN CANCER THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 17608002 | LACTATE DEHYDROGENASE INHIBITOR POLYPEPTIDES FOR USE IN THE TREATMENT OF CANCER | ROONEY, NORA MAUREEN | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1683 | 1 |
| 3774 | 1 |
| 1658 | 1 |
| 1656 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18843768 | DEVICE FOR HEART VALVE REPAIR | SNOW, BRUCE EDWARD | — | §102§112 | Non-Final OA | — | Pending | Sep 04, 2024 |
| 18580828 | PREVENTION AND/OR TREATMENT OF REWARD DYSREGULATION DISORDERS | HAUK TEODORO, PRICILA NMN | 1645 | §102§103§112 | Final Rejection | 14d | Pending | Jan 19, 2024 |
| 18562893 | MOLECULAR SIGNATURE FOR ASSESSING THE RESPONSIVENESS OF CANCER TO MITOCHONDRIA-TARGETED ANTIOXIDANTS | BELLAH, JEFFREY LAWRENCE | 1683 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18477795 | ELASTIC ENERGY STORING FOR PROSTHESIS OR ORTHOSIS | BARIA, DINAH N | 3774 | §102 | Final Rejection | — | Pending | Sep 29, 2023 |
| 18263756 | POLYPEPTIDE INHIBITORS OF LACTATE DEHYDROGENASE ACTIVITY FOR USE IN CANCER THERAPY | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §101§102§112 | Non-Final OA | — | Pending | Aug 01, 2023 |
| 17792011 | GENETICALLY MODIFIED BACTERIUM WITH ALTERED ENVELOP INTEGRITY AND USES THEREOF | STEADMAN, DAVID J | 1656 | §103DP | Non-Final OA | 26d | Pending | Jul 11, 2022 |
| 17608002 | LACTATE DEHYDROGENASE INHIBITOR POLYPEPTIDES FOR USE IN THE TREATMENT OF CANCER | ROONEY, NORA MAUREEN | 1641 | §112 | Final Rejection | — | Pending | Nov 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial